Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 319

1.

Neuroblastoma Patients' KIR and KIR-ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.

Erbe AK, Wang W, Carmichael L, Kim K, Mendonca EA, Song Y, Hess D, Reville PK, London WB, Naranjo A, Hank JA, Diccianni MB, Reisfeld RA, Gillies SD, Matthay KK, Cohn SL, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Gilman A, Yu AL, Sondel PM.

Clin Cancer Res. 2017 Oct 2. pii: clincanres.1767.2017. doi: 10.1158/1078-0432.CCR-17-1767. [Epub ahead of print]

PMID:
28972044
2.

Household food insecurity and dietary patterns in rural and urban American Indian families with young children.

Tomayko EJ, Mosso KL, Cronin KA, Carmichael L, Kim K, Parker T, Yaroch AL, Adams AK.

BMC Public Health. 2017 Jun 30;17(1):611. doi: 10.1186/s12889-017-4498-y.

3.

HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.

Erbe AK, Wang W, Reville PK, Carmichael L, Kim K, Mendonca EA, Song Y, Hank JA, London WB, Naranjo A, Hong F, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Miller JS, Gilman AL, Kahl B, Yu AL, Sondel PM.

Front Immunol. 2017 Jun 12;8:675. doi: 10.3389/fimmu.2017.00675. eCollection 2017.

4.

Defining Disease, Diagnosis, and Translational Medicine within a Homeostatic Perturbation Paradigm: The National Institutes of Health Undiagnosed Diseases Program Experience.

Gall T, Valkanas E, Bello C, Markello T, Adams C, Bone WP, Brandt AJ, Brazill JM, Carmichael L, Davids M, Davis J, Diaz-Perez Z, Draper D, Elson J, Flynn ED, Godfrey R, Groden C, Hsieh CK, Fischer R, Golas GA, Guzman J, Huang Y, Kane MS, Lee E, Li C, Links AE, Maduro V, Malicdan MCV, Malik FS, Nehrebecky M, Park J, Pemberton P, Schaffer K, Simeonov D, Sincan M, Smedley D, Valivullah Z, Wahl C, Washington N, Wolfe LA, Xu K, Zhu Y, Gahl WA, Tifft CJ, Toro C, Adams DR, He M, Robinson PN, Haendel MA, Zhai RG, Boerkoel CF.

Front Med (Lausanne). 2017 May 26;4:62. doi: 10.3389/fmed.2017.00062. eCollection 2017.

5.

Assessing histone demethylase inhibitors in cells: lessons learned.

Hatch SB, Yapp C, Montenegro RC, Savitsky P, Gamble V, Tumber A, Ruda GF, Bavetsias V, Fedorov O, Atrash B, Raynaud F, Lanigan R, Carmichael L, Tomlin K, Burke R, Westaway SM, Brown JA, Prinjha RK, Martinez ED, Oppermann U, Schofield CJ, Bountra C, Kawamura A, Blagg J, Brennan PE, Rossanese O, Müller S.

Epigenetics Chromatin. 2017 Mar 1;10:9. doi: 10.1186/s13072-017-0116-6. eCollection 2017.

6.

Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer.

Rampurwala M, Wisinski KB, Burkard ME, Ehsani S, O'Regan RM, Carmichael L, Kim K, Kolesar J, Tevaarwerk AJ.

Invest New Drugs. 2017 Feb;35(1):87-94. doi: 10.1007/s10637-016-0403-2. Epub 2016 Nov 8.

PMID:
27826831
7.

18F-FLT PET/CT imaging in patients with advanced solid malignancies treated with axitinib on an intermittent dosing regimen.

Scarpelli M, Bruce JY, Carmichael L, Eickhoff J, Kolesar J, Perlman S, Jeraj R, Liu G.

Cancer Chemother Pharmacol. 2016 Dec;78(6):1245-1252. Epub 2016 Nov 5.

PMID:
27817059
8.

FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma.

Erbe AK, Wang W, Goldberg J, Gallenberger M, Kim K, Carmichael L, Hess D, Mendonca EA, Song Y, Hank JA, Cheng SC, Signoretti S, Atkins M, Carlson A, Mier JW, Panka DJ, McDermott DF, Sondel PM.

Clin Cancer Res. 2017 May 1;23(9):2159-2168. doi: 10.1158/1078-0432.CCR-16-1874. Epub 2016 Oct 14.

PMID:
27742794
9.

Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2.

Wang W, Erbe AK, Gallenberger M, Kim K, Carmichael L, Hess D, Mendonca EA, Song Y, Hank JA, Cheng SC, Signoretti S, Atkins M, Carlson A, Weiss JM, Mier J, Panka D, McDermott DF, Sondel PM.

Cancer Immunol Immunother. 2016 Dec;65(12):1523-1532. Epub 2016 Sep 30.

PMID:
27695964
10.

Integrated Analysis of Multiple Biomarkers from Circulating Tumor Cells Enabled by Exclusion-Based Analyte Isolation.

Sperger JM, Strotman LN, Welsh A, Casavant BP, Chalmers Z, Horn S, Heninger E, Thiede SM, Tokar J, Gibbs BK, Guckenberger DJ, Carmichael L, Dehm SM, Stephens PJ, Beebe DJ, Berry SM, Lang JM.

Clin Cancer Res. 2016 Jul 11. doi: 10.1158/1078-0432.CCR-16-1021. [Epub ahead of print]

PMID:
27401243
11.

A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors.

Jin N, Lubner SJ, Mulkerin DL, Rajguru S, Carmichael L, Chen H, Holen KD, LoConte NK.

Oncologist. 2016 Jul;21(7):785-6. doi: 10.1634/theoncologist.2016-0060. Epub 2016 Jun 3.

12.

In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments.

Morris ZS, Guy EI, Francis DM, Gressett MM, Werner LR, Carmichael LL, Yang RK, Armstrong EA, Huang S, Navid F, Gillies SD, Korman A, Hank JA, Rakhmilevich AL, Harari PM, Sondel PM.

Cancer Res. 2016 Jul 1;76(13):3929-41. doi: 10.1158/0008-5472.CAN-15-2644. Epub 2016 May 6.

13.

Sorcin Links Pancreatic β-Cell Lipotoxicity to ER Ca2+ Stores.

Marmugi A, Parnis J, Chen X, Carmichael L, Hardy J, Mannan N, Marchetti P, Piemonti L, Bosco D, Johnson P, Shapiro JA, Cruciani-Guglielmacci C, Magnan C, Ibberson M, Thorens B, Valdivia HH, Rutter GA, Leclerc I.

Diabetes. 2016 Apr;65(4):1009-21. doi: 10.2337/db15-1334. Epub 2016 Jan 28.

14.

Describing Patterns of Care in Pancreatic Cancer: A Population-Based Study.

Burmeister EA, OʼConnell DL, Beesley VL, Goldstein D, Gooden HM, Janda M, Jordan SJ, Merrett ND, Payne ME, Wyld D, Neale RE; Pancreatic Cancer Patterns of Care Study Group.

Pancreas. 2015 Nov;44(8):1259-65. doi: 10.1097/MPA.0000000000000384.

PMID:
26262591
15.

Genome Modeling System: A Knowledge Management Platform for Genomics.

Griffith M, Griffith OL, Smith SM, Ramu A, Callaway MB, Brummett AM, Kiwala MJ, Coffman AC, Regier AA, Oberkfell BJ, Sanderson GE, Mooney TP, Nutter NG, Belter EA, Du F, Long RL, Abbott TE, Ferguson IT, Morton DL, Burnett MM, Weible JV, Peck JB, Dukes A, McMichael JF, Lolofie JT, Derickson BR, Hundal J, Skidmore ZL, Ainscough BJ, Dees ND, Schierding WS, Kandoth C, Kim KH, Lu C, Harris CC, Maher N, Maher CA, Magrini VJ, Abbott BS, Chen K, Clark E, Das I, Fan X, Hawkins AE, Hepler TG, Wylie TN, Leonard SM, Schroeder WE, Shi X, Carmichael LK, Weil MR, Wohlstadter RW, Stiehr G, McLellan MD, Pohl CS, Miller CA, Koboldt DC, Walker JR, Eldred JM, Larson DE, Dooling DJ, Ding L, Mardis ER, Wilson RK.

PLoS Comput Biol. 2015 Jul 9;11(7):e1004274. doi: 10.1371/journal.pcbi.1004274. eCollection 2015 Jul.

16.

Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with (18)F-3'deoxy-3'fluoro-L-thymidine positron emission tomography/computed tomography.

Bruce JY, Scully PC, Carmichael LL, Eickhoff JC, Perlman SB, Kolesar JM, Heideman JL, Jeraj R, Liu G.

Cancer Chemother Pharmacol. 2015 Jul;76(1):187-95. doi: 10.1007/s00280-015-2779-7. Epub 2015 May 29.

17.

Hepatitis C: extrahepatic manifestations.

Metts J, Carmichael L, Kokor W, Scharffenberg R.

FP Essent. 2014 Dec;427:32-5.

PMID:
25478648
18.

Hepatitis C: liver transplantation.

Metts J, Carmichael L, Kokor W, Scharffenberg R.

FP Essent. 2014 Dec;427:25-31.

PMID:
25478647
19.

Hepatitis C: existing and new treatments.

Metts J, Carmichael L, Kokor W, Scharffenberg R.

FP Essent. 2014 Dec;427:18-24.

PMID:
25478646
20.

Hepatitis C: prevalence, transmission, screening, and prevention.

Metts J, Carmichael L, Kokor W, Scharffenberg R.

FP Essent. 2014 Dec;427:11-7.

PMID:
25478645

Supplemental Content

Loading ...
Support Center